WALPAR NUTRITIONS LTD. | NEULAND LABS | WALPAR NUTRITIONS LTD./ NEULAND LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | - | 67.9 | - | View Chart |
P/BV | x | 3.1 | 14.8 | 21.1% | View Chart |
Dividend Yield | % | 0.0 | 0.1 | - |
WALPAR NUTRITIONS LTD. NEULAND LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WALPAR NUTRITIONS LTD. Mar-24 |
NEULAND LABS Mar-24 |
WALPAR NUTRITIONS LTD./ NEULAND LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 154 | 7,450 | 2.1% | |
Low | Rs | 78 | 1,790 | 4.4% | |
Sales per share (Unadj.) | Rs | 133.0 | 1,214.8 | 11.0% | |
Earnings per share (Unadj.) | Rs | 4.1 | 233.9 | 1.8% | |
Cash flow per share (Unadj.) | Rs | 8.0 | 280.4 | 2.8% | |
Dividends per share (Unadj.) | Rs | 0 | 14.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.3 | 0.0% | |
Book value per share (Unadj.) | Rs | 30.2 | 999.8 | 3.0% | |
Shares outstanding (eoy) | m | 4.70 | 12.83 | 36.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 3.8 | 22.9% | |
Avg P/E ratio | x | 28.0 | 19.8 | 141.7% | |
P/CF ratio (eoy) | x | 14.5 | 16.5 | 88.0% | |
Price / Book Value ratio | x | 3.8 | 4.6 | 83.1% | |
Dividend payout | % | 0 | 6.0 | 0.0% | |
Avg Mkt Cap | Rs m | 545 | 59,274 | 0.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 32 | 2,571 | 1.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 625 | 15,586 | 4.0% | |
Other income | Rs m | 2 | 125 | 1.7% | |
Total revenues | Rs m | 627 | 15,711 | 4.0% | |
Gross profit | Rs m | 48 | 4,626 | 1.0% | |
Depreciation | Rs m | 18 | 597 | 3.0% | |
Interest | Rs m | 7 | 140 | 4.8% | |
Profit before tax | Rs m | 25 | 4,014 | 0.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5 | 1,014 | 0.5% | |
Profit after tax | Rs m | 19 | 3,001 | 0.6% | |
Gross profit margin | % | 7.6 | 29.7 | 25.6% | |
Effective tax rate | % | 22.0 | 25.2 | 87.0% | |
Net profit margin | % | 3.1 | 19.3 | 16.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 246 | 9,211 | 2.7% | |
Current liabilities | Rs m | 167 | 4,277 | 3.9% | |
Net working cap to sales | % | 12.7 | 31.7 | 40.3% | |
Current ratio | x | 1.5 | 2.2 | 68.6% | |
Inventory Days | Days | 13 | 10 | 132.1% | |
Debtors Days | Days | 785 | 875 | 89.7% | |
Net fixed assets | Rs m | 124 | 9,115 | 1.4% | |
Share capital | Rs m | 47 | 129 | 36.4% | |
"Free" reserves | Rs m | 95 | 12,698 | 0.7% | |
Net worth | Rs m | 142 | 12,827 | 1.1% | |
Long term debt | Rs m | 41 | 449 | 9.1% | |
Total assets | Rs m | 371 | 18,326 | 2.0% | |
Interest coverage | x | 4.7 | 29.7 | 15.9% | |
Debt to equity ratio | x | 0.3 | 0 | 820.8% | |
Sales to assets ratio | x | 1.7 | 0.9 | 198.2% | |
Return on assets | % | 7.0 | 17.1 | 41.1% | |
Return on equity | % | 13.7 | 23.4 | 58.6% | |
Return on capital | % | 17.3 | 31.3 | 55.3% | |
Exports to sales | % | 0 | 75.4 | 0.0% | |
Imports to sales | % | 0 | 11.5 | 0.0% | |
Exports (fob) | Rs m | NA | 11,755 | 0.0% | |
Imports (cif) | Rs m | NA | 1,795 | 0.0% | |
Fx inflow | Rs m | 0 | 11,755 | 0.0% | |
Fx outflow | Rs m | 0 | 1,795 | 0.0% | |
Net fx | Rs m | 0 | 9,960 | 0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 54 | 2,612 | 2.0% | |
From Investments | Rs m | -36 | -1,497 | 2.4% | |
From Financial Activity | Rs m | -18 | -693 | 2.6% | |
Net Cashflow | Rs m | 0 | 422 | -0.1% |
Indian Promoters | % | 68.4 | 32.6 | 209.7% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 33.2 | - | |
FIIs | % | 0.0 | 26.5 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 31.6 | 67.4 | 46.9% | |
Shareholders | 335 | 34,567 | 1.0% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare WALPAR NUTRITIONS LTD. With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | WALPAR NUTRITIONS LTD. | NEULAND LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 0.00% | -0.69% | 0.88% |
1-Month | 3.40% | 7.13% | 1.20% |
1-Year | -52.85% | 183.68% | 46.18% |
3-Year CAGR | -18.38% | 107.01% | 19.62% |
5-Year CAGR | -11.47% | 100.48% | 26.11% |
* Compound Annual Growth Rate
Here are more details on the WALPAR NUTRITIONS LTD. share price and the NEULAND LABS share price.
Moving on to shareholding structures...
The promoters of WALPAR NUTRITIONS LTD. hold a 68.4% stake in the company. In case of NEULAND LABS the stake stands at 32.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of WALPAR NUTRITIONS LTD. and the shareholding pattern of NEULAND LABS.
Finally, a word on dividends...
In the most recent financial year, WALPAR NUTRITIONS LTD. paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
NEULAND LABS paid Rs 14.0, and its dividend payout ratio stood at 6.0%.
You may visit here to review the dividend history of WALPAR NUTRITIONS LTD., and the dividend history of NEULAND LABS.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks experienced a notable rally alongside US equity futures on Monday, marking a positive turn for the markets. The dollar retreated against other currencies as bond yields declined.